Multiple Myeloma

>

Latest News

Busulfan/melphalan elicited higher PFS among patients with ISS2 or ISS3 disease, and melphalan-200 improved PFS in ISS1 disease.
Busulfan-Enhanced VRD Regimen Improves Efficacy in NDMM

July 3rd 2025

Busulfan/melphalan elicited higher PFS among patients with ISS2 or ISS3 disease, and melphalan-200 improved PFS in ISS1 disease.

The expert panel discussed the efficacy observed with cilta-cel in patients with relapsed/refractory multiple myeloma.
Comparing CAR T Safety, Efficacy in Relapsed/Refractory Multiple Myeloma

July 2nd 2025

Data supporting the FDA decision came from the phase 1/2 LINKER-MM1 (NCT03761108) trial.
Linvoseltamab Earns FDA Accelerated Approval for R/R Multiple Myeloma

July 2nd 2025

89Zr-DFO-daratumumab Has Potential Imaging Benefits in Non-FDG–Avid Multiple Myeloma
89Zr-DFO-daratumumab Has Potential Imaging Benefits in Non-FDG–Avid Multiple Myeloma

June 30th 2025

FDA Removes REMS, Lessens Requirements of Liso-cel/Ide-cel in Blood Cancers
FDA Removes REMS, Lessens Requirements of Liso-cel/Ide-cel in Blood Cancers

June 27th 2025

Latest CME Events & Activities

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

View More

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

View More

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

View More

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

View More

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

View More

Community Practice Connections™: Selecting and Sequencing Therapy for Patients with DLBCL in an Era of Expanding Options

View More

BURST Expert Illustrations and Commentaries™: Exploring the Mechanistic Rationale for CSF-1R– Directed Treatment in Chronic GVHD

View More

(CME) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

View More

(COPE) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

View More

Community Practice Connections™: 6th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes

View More

Community Practice Connections™: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer

View More

More News